GA101 Shows Gains in Pivotal CLL TrialOncLiveThe agent also delivered higher response rates than rituximab (Rituxan) plus chlorambucil did in the same population, although full data comparing the two antibodies in a head-to-head stage of the phase III …
|
New entrants to multiple sclerosis market will drive 10% pa growth through 2018
The Pharma Letter … reformulations of platform injectables and three highly efficacious monoclonal antibodies – Genzyme/Bayer’s (BAYN: DE) Lemtrada (alemtuzumab), Roche (ROG: SIX)/Genentech’s ocrelizumab and Biogen Idec/AbbVie’s (NYSE: ABBV) daclizumab. |
|
Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter …
DailyFinance We estimate that approximately $82 million of TECFIDERA revenues in the second quarter represent inventory in the channel while revenue generated from underlying patient demand was approximately $110 million. RITUXAN® (rituximab) revenues from … Biogen Idec Inc (BIIB) Management Discusses Q2 2013 Results – Earnings Call …Seeking Alpha |
Gilead Sciences, Inc. (GILD) CEO Discusses Q2 2013 Results – Earnings Call …Seeking AlphaAnother presentation was on the combination use of idelalisib and rituximab in elderly treatment naive CLL SLL patients. In this study, the overall response rate…
|
Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter …
MarketWatch RITUXAN(R) (rituximab) revenues from our unconsolidated joint business arrangement were $289 million for the quarter, an increase of 1% compared to the second quarter of 2012. “With a strong start for TECFIDERA in the U.S., as well as approvals in … Biogen Idec Inc (BIIB) Management Discusses Q2 2013 Results – Earnings Call …Seeking Alpha |
Celgene Corporation (CELG) CEO Discusses Q2 2013 Results – Earnings Call …Seeking AlphaThe results for the CALGB 5803 Phase II study of REVLIMID plus rituximab in patients with previously untreated follicular lymphoma were presented during the Intern…
|
Gilead Sciences Announces Second Quarter 2013 Financial Results
DailyFinance Results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101) in combination with rituximab for older patients with treatment-naïve chronic lymphocytic leukemia. This regimen achieved a complete response rate of 19 percent and an … Gilead Sciences, Inc. (GILD) CEO Discusses Q2 2013 Results – Earnings Call …Seeking Alpha |
Use of Surveillance CT Scans to Detect DLBCL RelapseCancer NetworkIt is potentially curable with a combination of chemotherapy and targeted immunotherapy with rituximab (Rituxan). Up to one-third of patients relapse following remission. Relapsed DLBCL …
Biogen Idec Inc (BIIB) Management Discusses Q2 2013 Results – Earnings Call …Seeking AlphaWe continue to make progress with our mid-stage pipeline and expect 3 pivotal readouts over the next 3 years: daclizumab in 2014, TYSABRI and SPMS in 2015 and p…
|
The Multiple Sclerosis Market Will Grow 10 Percent Annually Through 2018 As …
Sacramento Bee … be followed by the emergence of more-convenient reformulations of platform injectables and three highly efficacious monoclonal antibodies— Genzyme/Bayer HealthCare’s Lemtrada, Roche/Genentech’s ocrelizumab and Biogen Idec/AbbVie’s daclizumab. |